Area of research
Radiology, Nuclear Medicine and Imaging · Molecular Biology
Research interest
Research interests include Monoclonal and Polyclonal Antibodies Research, Glycosylation and Glycoproteins Research, Chronic Lymphocytic Leukemia Research, and Complement system in diseases.
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy
Impact of structural modifications of IgG antibodies on effector functions
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.
Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation
Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation.
Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8<sup>+</sup> T-cell immunity towards cancer cells.
Single-cell Sequencing of Circulating Human Plasmablasts during Staphylococcus aureus Bacteremia.
Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation.
The Influence of Human IgG Subclass and Allotype on Complement Activation
The Influence of Human IgG Subclass and Allotype on Complement Activation.
Promoting Fc-Fc interactions between anti-capsular antibodies provides strong immune protection against <i>Streptococcus pneumoniae</i>.
Supplementary Figure Legends from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Fig S4 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Fig S5 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Fig S3 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Supplementary Figure Legends from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Data from Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
Data from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Fig S3 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Data from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Fig S1 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Fig S2 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Supplementary Data from Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
Author response: Promoting Fc-Fc interactions between anti-capsular antibodies provides strong immune protection against Streptococcus pneumoniae
Fig S2 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Fig S1 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Supplementary Data from Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
Fig S5 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Data from Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
Fig S4 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory